ATMOSNCT07720375
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 4 → 7 locations
- Notable Eligibility criteria expanded, about 26 words
- Study sites: 4 to 6
- Secondary endpoints: details revised at 5 of 5 entries
- Notable Eligibility criteria revised
- Study sites: 3 to 4
- Notable Recruitment opened
- Trial sites expanded: 0 → 3 locations
- Start date changed from estimate of Jul 31, 2026 to Aug 5, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Time from intervention assignment to first moderate or severe pulmonary exacerbation
Timeframe: Up to Week 52
Secondary (5)
Annualized rate of pulmonary exacerbations
Post bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 24
Incidence of Treatment-Emergent (TE) Adverse Events (AE)
Incidence of TE Serious Adverse Events (SAEs)
Change from Baseline in Quality of life questionnaire-bronchiectasis (QOL-B) Respiratory Symptoms Domain Scores at Week 24
Arms and interventions
Galvokimig Dose 1 ArmExperimental
Participants randomly assigned to this arm will receive Galvokimig Dose 1
Galvokimig Dose 2 ArmExperimental
Participants randomly assigned to this arm will receive Galvokimig Dose 2
Galvokimig Dose 3 ArmExperimental
Participants randomly assigned to this arm will receive Galvokimig Dose 3
Placebo ArmPlacebo comparator
Participants randomly assigned to this arm will receive a matching Placebo.
Biologicals: Galvokimig, Placebo
Sites
7 sites in 1 country